Shuozi Liu

Precision targeting and alternative effector cells: Revolutionizing CAR-based therapy for T-cell malignancies.

T-cell malignancies are highly heterogeneous and associated with high relapse rate and poor prognosis. While chimeric antigen receptor-T (CAR-T) cell therapy has achieved remarkable success in relapsed or refractory B-cell malignancies, its application in T-cell malignancies rema...